Immuron Reports Positive Results in NASH Clinical Trial
Filed with ASX · · 6 pages · English
Story so far
Earlier from Immuron
- Correction to False and Misleading News Release
- Appendix 4D - Half Year Financial Report - 31 Dec 2017
- Travelan Revenue Grows Significantly in US and Australia
- US Defence Depart Report-Travelan Targets Priority Pathogens
- Immuron to Receive $2.16M R&D Tax Concession Cash Refund
Later from Immuron
- Immuron Announces A$5.1M Private Placement to U.S. Fund
- Travelan Sales Continue to Soar in Third Quarter of FY2018
- IMC Preclinical Study Reports Reduction in Colitis Symptoms
- Immuron Announces Board Appointment
- European Patent Gramted for Nash Treatment
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron